Literature DB >> 31848139

Chylothorax: complication attributed to dasatinib use.

Abdullah Al-Abcha1, Mian Harris Iftikhar2, Fawzi Abu Rous3, Heather Laird-Fick3.   

Abstract

A 63-year-old woman with a medical history of chronic myelogenous leukaemia treated with dasatinib, chronic obstructive pulmonary disease and heart failure with preserved ejection fraction presented with difficulty in breathing. Chest X-ray showed large right-sided pleural effusion, which was confirmed on a CT angiogram of the chest. Echocardiogram showed an ejection fraction of 61% with moderate to severely dilated right ventricle and right ventricular systolic pressure of 60 mm Hg. Diagnostic and therapeutic thoracentesis was performed, and 2.2 L of pleural fluid was removed. Pleural fluid analysis was consistent with chylothorax. Significant symptomatic improvement was noted after thoracentesis. In the absence of an alternate explanation, chylothorax was attributed to dasatinib, which was switched to nilotinib. This resulted in resolution of her pleural effusions. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dasatinib; haematology (drugs and medicines); respiratory medicine; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2019        PMID: 31848139      PMCID: PMC6936595          DOI: 10.1136/bcr-2019-231653

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

Review 1.  Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.

Authors:  Jorge E Cortes; Carlos A Jimenez; Michael J Mauro; Alex Geyer; Javier Pinilla-Ibarz; B Douglas Smith
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-09-17

Review 2.  Chylothorax: aetiology, diagnosis and therapeutic options.

Authors:  Emmet E McGrath; Zoe Blades; Paul B Anderson
Journal:  Respir Med       Date:  2009-09-18       Impact factor: 3.415

Review 3.  Cellular functions regulated by Src family kinases.

Authors:  S M Thomas; J S Brugge
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

4.  Dasatinib.

Authors:  Markus Lindauer; Andreas Hochhaus
Journal:  Recent Results Cancer Res       Date:  2018

5.  The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo.

Authors:  F Luton; M Vergés; J P Vaerman; M Sudol; K E Mostov
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

Review 6.  The use of octreotide in the treatment of chylothorax following cardiothoracic surgery.

Authors:  Nur A Ismail; Jacqueline Gordon; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2015-03-16

Review 7.  Chylothorax: diagnosis and management in children.

Authors:  Manuel Soto-Martinez; John Massie
Journal:  Paediatr Respir Rev       Date:  2009-09-26       Impact factor: 2.726

8.  Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.

Authors:  Alessandra Iurlo; Sara Galimberti; Elisabetta Abruzzese; Mario Annunziata; Massimiliano Bonifacio; Roberto Latagliata; Patrizia Pregno; Dario Ferrero; Federica Sorà; Ester Maria Orlandi; Carmen Fava; Daniele Cattaneo; Cristina Bucelli; Gianni Binotto; Ester Pungolino; Mario Tiribelli; Antonella Gozzini; Gabriele Gugliotta; Fausto Castagnetti; Fabio Stagno; Giovanna Rege-Cambrin; Bruno Martino; Luigiana Luciano; Massimo Breccia; Simona Sica; Monica Bocchia; Fabrizio Pane; Giuseppe Saglio; Gianantonio Rosti; Giorgina Specchia; Agostino Cortelezzi; Michele Baccarani
Journal:  Ann Hematol       Date:  2017-10-02       Impact factor: 3.673

9.  Dasatinib-induced pleural effusion: Chylothorax, an option to consider.

Authors:  Lucía Ferreiro; Esther San-José; Juan Suárez-Antelo; Luis Valdés
Journal:  Ann Thorac Med       Date:  2016 Oct-Dec       Impact factor: 2.219

Review 10.  Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine "Goreisan".

Authors:  Hisashi Sasaki; Yoshifumi Kimizuka; Hiraku Ogata; Yosuke Okada; Shinichiro Ota; Tomoya Sano; Chie Watanabe; Yohei Maki; Takayuki Yamamoto; Yoichi Tagami; Jun Miyata; Nobuyoshi Hayashi; Yuji Fujikura; Akihiko Kawana
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

View more
  3 in total

1.  Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.

Authors:  Or Kalchiem-Dekel; Christina J Falcon; Christine M Bestvina; Dazhi Liu; Lauren A Kaplanis; Clare Wilhelm; Jordan Eichholz; Guilherme Harada; Lori J Wirth; Subba R Digumarthy; Robert P Lee; David Kadosh; Robin B Mendelsohn; Jessica Donington; Justin F Gainor; Alexander Drilon; Jessica J Lin
Journal:  J Thorac Oncol       Date:  2022-07-02       Impact factor: 20.121

2.  Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review.

Authors:  Chao-Chin Hsu; Jui-Feng Hsu; Kuan-Li Wu
Journal:  Respirol Case Rep       Date:  2021-05-07

3.  Recurrent Chylous Pleural Effusions in a Patient Treated With Dasatinib.

Authors:  Syed Alishan Nasir; Hugo Calavia Liano; Christopher Manfredi
Journal:  Cureus       Date:  2022-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.